Hunan Jiudian Pharmaceutical found compliant in latest supervision report

Western Securities Co., Ltd. conducted its 2025 annual continuous supervision regular on-site inspection of Hunan Jiudian Pharmaceutical Co., Ltd. from December 15 to December 19, 2025. The inspection focused on the 2025 period and covered critical areas including company governance, internal controls, and information disclosure.

The inspection concluded that Hunan Jiudian Pharmaceutical's corporate governance structures, including its articles of association and governance systems, are complete and compliant. Board and shareholder meeting records were found to be accurate and well-preserved. Furthermore, the company's internal audit department and audit committee were found to be in line with regulatory requirements, consistently reporting on work plans and findings.

Regarding information disclosure, all released announcements were consistent with actual conditions, complete, and did not omit any significant events. The company also demonstrated effective mechanisms for protecting its interests from controlling shareholders and related parties. Notably, the report highlighted a resolution on August 21, 2025, from the company's fourth board of directors and supervisors meetings, which approved a change in the use of proceeds from convertible bond issuance. Overall, the inspection found no issues requiring rectification by the issuer.